Semaglutide (Wegovy/Ozempic) is the closest currently available alternative, producing 14-16% average weight loss compared to tirzepatide at 18-22%
We also offer S-Acetyl Glutathione Ultra with NAC when combined direct and precursor support is appropriate
Tofu is a sleeper hit for GLP-1 dinners
For injectable tirzepatide, we have evidence from multiple Phase III clinical trials involving over 10,000 participants, published in the New England Journal of Medicine, The Lancet, and JAMA
Efficacy endpoints for semaglutide compared to placebo, stratified by obesity class at baseline, were assessed using both the full analysis set (all randomized participants according to the intention-to-treat principle, regardless of treatment discontinuation) and the on-treatment data (including only patients receiving allocated study medication)